EcoDrugPlus

Cytochrome P450 3a28

Ensembl ID : ENSBBBG00000010627
Gene Symbol: LOC104992728
2 Cross references
695 Possible Orthologues:

Cytochrome P450 Family 17 Subfamily A Member 1

Ensembl ID : ENSBBBG00000022580
Gene Symbol: CYP17A1
3 Cross references
211 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSBBBG00000025027
Gene Symbol: CYP19A1
3 Cross references
317 Possible Orthologues:

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSBBBG00000016681
Gene Symbol: CYP26A1
3 Cross references
208 Possible Orthologues:

Cytochrome P450 Family 46 Subfamily A Member 1

Ensembl ID : ENSBBBG00000000415
Gene Symbol: CYP46A1
3 Cross references
260 Possible Orthologues:

Dihydrofolate Reductase

Ensembl ID : ENSBBBG00000003536
Gene Symbol: DHFR
2 Cross references
348 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSBBBG00000017286
Gene Symbol: DHODH
3 Cross references
173 Possible Orthologues:

Dipeptidyl Peptidase 4

Ensembl ID : ENSBBBG00000007218
Gene Symbol: DPP4
3 Cross references
286 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSBBBG00000022964
Gene Symbol: DDR2
3 Cross references
264 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSBBBG00000005565
Gene Symbol: DRD1
3 Cross references
262 Possible Orthologues:

Dopamine Receptor D2

Ensembl ID : ENSBBBG00000011207
Gene Symbol: DRD2
3 Cross references
222 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSBBBG00000016079
Gene Symbol: DRD3
3 Cross references
209 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).